Pieris Pharmaceuticals, Inc. (PIRS) Given a $9.00 Price Target by HC Wainwright Analysts
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) received a $9.00 target price from equities researchers at HC Wainwright in a research note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 80.00% from the company’s previous close.
Separately, BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Four research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $9.00.
Shares of Pieris Pharmaceuticals (PIRS) traded down 1.96% during midday trading on Wednesday, reaching $5.00. The company had a trading volume of 340,930 shares. The firm’s market capitalization is $221.54 million. Pieris Pharmaceuticals has a one year low of $1.30 and a one year high of $6.58. The company has a 50 day moving average price of $5.64 and a 200-day moving average price of $5.64.
In other Pieris Pharmaceuticals news, Director James A. Geraghty bought 10,000 shares of the stock in a transaction on Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, with a total value of $48,200.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $48,200. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Allan Reine bought 65,000 shares of the stock in a transaction on Thursday, August 17th. The shares were acquired at an average cost of $4.82 per share, for a total transaction of $313,300.00. Following the acquisition, the insider now directly owns 45,000 shares in the company, valued at $216,900. The disclosure for this purchase can be found here. Insiders own 4.05% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Voya Investment Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $100,000. State of Wisconsin Investment Board purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $132,000. The Manufacturers Life Insurance Company grew its position in shares of Pieris Pharmaceuticals by 1,106.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 29,150 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $162,000. Finally, Rhumbline Advisers purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at $184,000. 50.50% of the stock is currently owned by institutional investors and hedge funds.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.